Prolonged controlled delivery of nerve growth factor using porous silicon nanostructures

Although nerve growth factor (NGF) is beneficial for the treatment of numerous neurological and non-neurological diseases, its therapeutic administration represents a significant challenge, due to the difficulty to locally deliver relevant doses in a safe and non-invasive manner. In this work, we em...

Full description

Saved in:
Bibliographic Details
Published in:Journal of controlled release 2017-07, Vol.257, p.51-59
Main Authors: Zilony, Neta, Rosenberg, Michal, Holtzman, Liran, Schori, Hadas, Shefi, Orit, Segal, Ester
Format: Article
Language:English
Subjects:
Animals
Cell Differentiation - drug effects
Cells, Cultured
Controlled release
Delayed-Action Preparations - chemistry
Differentiation
Dorsal root ganglia
Ganglia, Spinal - cytology
Ganglia, Spinal - drug effects
Mice, Inbred C57BL
Nanostructures - chemistry
Nerve growth factor
Nerve Growth Factors - administration & dosage
Nerve Growth Factors - pharmacology
Neurogenesis - drug effects
Neurons - cytology
Neurons - drug effects
PC12
PC12 Cells
Porosity
Porous silicon
Rats
Silicon - chemistry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although nerve growth factor (NGF) is beneficial for the treatment of numerous neurological and non-neurological diseases, its therapeutic administration represents a significant challenge, due to the difficulty to locally deliver relevant doses in a safe and non-invasive manner. In this work, we employ degradable nanostructured porous silicon (PSi) films as carriers for NGF, allowing its continuous and prolonged release, while retaining its bioactivity. The PSi carriers exhibit high loading efficacy (up to 90%) of NGF and a continuous release, with no burst, over a period of>26days. The released NGF bioactivity is compared to that of free NGF in both PC12 cells and dissociated dorsal root ganglion (DRG) neurons. We show that the NGF has retained its bioactivity and induces neurite outgrowth and profound differentiation (of >50% for PC12 cells) throughout the period of release within a single administration. Thus, this proof-of-concept study demonstrates the immense therapeutic potential of these tunable carriers as long-term implants of NGF reservoirs and paves the way for new localized treatment strategies of neurodegenerative diseases. [Display omitted]
ISSN:0168-3659
1873-4995
DOI:10.1016/j.jconrel.2016.12.008